The immunopathology of systemic lupus erythematosus (SLE) includes polyclonal activation of B lymphocytes. In addition to hypergammaglobulinaemia, antibodies to many nuclear antigens are produced.' Among these, antibody to double-stranded DNA (dsDNA) is historically the most important, and its presence constitutes one of the 11 criteria commensurate with a diagnosis of SLE according to the revised criteria of the American Rheumatism Association.2 The reported prevalence of antibodies to dsDNA in SLE varies from 40%' to 88%. 4 Although this variability results to some extent from the choice of patient group, much is likely to be due to the choice of assay method. These antibodies were originally measured using a Farr ammonium sulphate precipitation method' but have since been measured by double diffusion,' passive haemagglutination, 6 Crithidia luciliae staining,7 millipore filter assay' and a great number of radioimmunoassays (RIAs) and enzyme linked immunosorbent assays (ELISAs) . These 100 mM NaCl, 5 mM ZnCl2. S1 nuclease was added (100 U/mg DNA) and the mixture was incubated for three hours at 37°C before being dialysed overnight against buffer A. The DNA concentration was determined at 260 nm (OD260 of 1-07 is equivalent to a DNA concentration of 50 ,ug/ml). ssDNA was prepared by boiling dsDNA for 15 minutes and cooling rapidly on ice. Protein was measured by the method of Maddy and Spooner.'3 The strandedness of the DNA preparations was assessed by benzoylated naphthoylated DEAE cellulose (BNDC) chromatography.'4 Briefly, DNA was added to a BNDC column equilibrated with 0-3M NaCL buffer. dsDNA is eluted with 1 0 M NaCl buffer and ssDNA and/or dsDNA with ss regions is eluted with 1 0 M NaCl/50% formamide buffer.
SERA
The 66 sera used in the commercial kit comparison were chosen randomly from patients with suspected or definite connective tissue disease for which a dsDNA autoantibody response had been requested. These sera were numbered 1 to 66 and it is these numbers which are used to identify the various sera in the text and tables. The choice of sera was not made on diagnostic criteria but to provide sera with a broad spectrum of negative and positive results as determined by the IDS RIA. An additional 154 sera screened only with the IDS RIA and the in-house ELISA were chosen in a similar manner to investigate the role of non-DNA, non-IgG antibodies in the production of false positive results. Of the 220 patients investigated, 56 had definite SLE; nine patients had definite or suspected variants of SLE such as discoid lupus or subacute lupus erythematosus; one had drug induced lupus; and five patients had a definite connective tissue disease other than SLE. Sera from the remaining 125 patients had been sent for analysis to confirm or preclude possible connective tissue disease because of their clinical presentation. These were renal (n = 34), haematological (n = 14), dermatological (n = 11), neurological (n = 7), vasculitic (n = 5), pulmonary (n = 4), cardiac (n = 4), rheumatoid (n = 9) and miscellaneous (n = 37).
Results Table 1 shows that the positivity of the 66 samples using commercial kits varied from 36 (55%) with the IDS RIA to five (7-6%) with the BioHyTech ELISA. Antigen specific analysis showed that nine sera (14%) were positive for antibodies to dsDNA and that 18 (27%) were Intennediate (500-6-99) 11 7 4 Positive (>700) 25 6 19 Sera scored as positive by ELI SA were positive in one more of the three ELISAs positive for antibodies to ssDNA. In all, 20 sera (30%) were positive for ds or ssDNA, or both. Nine sera (14%) also had antibodies to histones and eight (12%) had IgM antibodies to nDNA. Table 2 divides the 66 sera on the basis of their IDS RIA score that is, negative (less than 5 00 mg/ml), intermediate (500-6-99 mg/ml), and positive (more than 7 00 mg/ ml). All those sera scoring positive in one or more of the commercial ELISAs ( (table 1) . All of these, however, were found either in association with IgG antibodies to DNA or in sera which were negative in all four commercial assays. Table 6 shows the breakdown of results from all 220 sera used in this study and compares them with the results obtained from sera from patients with definite SLE. Of all 220 sera, 130 were positive using the IDS RIA but only 48 had measurable antibodies to dsDNA. The percentage incidence in all antibody categories is much higher in the SLE group but the relative incidences within each group are similar. Thus in both groups the incidence of antibodies to ssDNA is about 50% greater than that of antibodies to dsDNA. With only one exception, all sera (from both groups) with antibodies to dsDNA or ssDNA were recorded as positive using the IDS RIA.
The IDS RIA results were compared with those obtained from IgG-anti-dsDNA, IgGanti-ssDNA, and IgM-anti-nDNA using the paired Student's t test. All associations were significant (p < 0 05) and the correlations (r) were 0 476, 0 680, and 0 613, respectively. The binding of anti-ssDNA antibodies to ssDNA was completely abolished by prior incubation with ssDNA at a concentration of 300 Mg/ml; dsDNA up to a concentration of 550 Mg/ml had no effect whatsoever.
Analysis of Sigma calf thymus nDNA showed that it contained 2-3% protein (w/w). After digestion with proteinase K and phase separation this had decreased to less than 0 5%. Measurement of the strandedness of the DNA preparations showed that all the purified dsDNA was eluted from the BNDC column by the 1 0 M NaCl buffer (indicating 100% dsDNA) whereas none of the ssDNA was eluted with his buffer, all being eluted with the 1'0 M NaCl/50% formamide buffer (indicating 100% ssDNA). Using this system, untreated Sigma calf thymus nDNA was found to contain 22-1% dsDNA. yield more positive results than the Bioscot ELI SA, but table 3 shows that of the nine sera positive using IDS and negative using Bioscot, only one had IgM antibodies. Therefore these differences among the ELISAs do not seem to result from the differing specificities of the conjugates used.
Of the 30 sera reported as negative with the IDS RIA, six were positive by one or more of the ELISAs. Such a discrepancy is not surprising, but the finding that four of the five BioHyTech positive results were in this group is indeed surprising. Clearly the latter kit does not share the same consensus result with the other three kits. Eleven sera gave an IDS RIA score of between 5-00 and 6-99 mg/l and these were assigned into an intermediate group.
None was found to contain antibodies to dsDNA and most of these sera (n = 7) were also negative in all three ELISAs. Nevertheless, three were recorded as positive by the IDS ELISA and one with the Bioscot ELISA.
Twenty five sera were reported as strongly positive using the IDS RIA (more than 7 00 mg/l). Even here, however, six sera were recorded as negative by all three ELISAs. One of these six had dsDNA antibodies while the rest had no measurable antibodies whatsoever (results not shown). Of the 19 also reported as positive by one or more of the ELISAs, 18 were detected by the IDS kit, 15 by the Bioscot kit, and only one by the BioHyTech kit. Table 3 , however, shows that only six of these 19 sera had measurable antibodies to dsDNA whereas most (n = 4) had antibodies to ssDNA. This tNine of the total sera (two in the SLE group) were negative for IgG antibodies to DNA but positive using the IDS RIA.
message is emphasised further in tables 4 and 5.
In the former the nine sera found to contain antibodies to dsDNA have been listed. Seven ofthese sera (although not the same seven) were detected by the IDS RIA, IDS ELISA, and Bioscot ELISA, while the BioHyTech ELISA detected only two. Table 5 lists the 12 sera which contained antibodies to ssDNA in the absence of anti-dsDNA. Most were reprted as positive by the IDS RIA (n = I 1) and the IDS ELISA (n = 9). Five were reported as positive using the Bioscot ELISA and none with the BioHyTech ELISA. The IDS RIA, IDS ELISA, and Bioscot ELISA are equally efficient at detecting antibodies to dsDNA (seven out of nine) whereas the BioHyTech ELISA detected only two out of nine dsDNA antibody positive results. The IDS RIA, however, also records as positive virtually all sera with antibodies to ssDNA (eleven out of twelve). The Bioscot ELISA is much less sensitive to ssDNA antibodies than the IDS ELISA (five out of 12 compared with nine out of 12). Thus these kits clearly detect antibodies to ssDNA, in some cases more frequently than antibodies to dsDNA, and the most likely cause is contamination of the dsDNA with ss regions, as has been suggested previously.'" The care taken in the work reported here to remove protein contaminants as well as ss regions from the commercially supplied DNA has yielded material which was 100% pure dsDNA, as measured by BNDC chromatography, and this has consequently resulted in a much more specific assay. In support of this, seven sera were found which were positive using unpurified nDNA but which were subsequently found to be negative using the purified dsDNA (results not shown). Of these seven, five were positive for antibodies to ssDNA. Notably, all seven were recorded as positive using the IDS RIA, the ELISA positivity being six (IDS), five (Bioscot), and 0 (BioHyTech). The Sigma nDNA used here was found to contain only 22-1 % pure dsDNA, the rest being either pure ssDNA or more likely dsDNA with several segments of ssDNA. The detection of anti-ssDNA using nDNA as target antigen is therefore easily explained and one can only guess whether such a phenomenon may explain some of the poor specificity observed here with the commercial kits.
The possible role of non-anti-DNA, nonIgG antibodies in the production of false positive results was investigated by extending the study to 220 sera. All were assayed using the IDS RIA as well as the in-house ELISA. The results are given in table 6 which compares all 220 sera with the 56 sera from patients with definite SLE. In both groups anti-ssDNA is more prevalent than anti-dsDNA, and more importantly all those sera which had ssDNA antibodies exclusively (with one exception) were recorded as positive using the IDS RIA. In total, nine IDS RIA positive sera were found which were negative for antibodies to dsor ssDNA but had IgG antibodies to histones or IgM antibodies to nDNA. Thus in 50 sera that were positive in the IDS RIA no specific antibodies could be found. Such a non-specific ammonium sulphate precipitation method is easily influenced by the total serum Ig, and in this particular patient group where hypergammaglobulinaemia is very common it is very likely that there is significant coprecipitation of non-specifically adsorbed labelled DNA. This lack of specificity for antidsDNA is further confirmed by the finding that the IDS RIA results correlate much better with IgG-anti-ssDNA and IgM-anti-nDNA than they do with IgG-anti-dsDNA.
In conclusion, it is difficult to decide what the BioHyTech ELISA is measuring, although it did detect two out of nine of the anti-dsDNA sera. The other three kits were equally efficient at detecting anti-dsDNA antibodies (seven out of nine) but, to varying degrees, produced false positive results. A major fault was the detection of antibodies to ssDNA, this being particularly noticeable in the IDS RIA and IDS ELISA, and this was thought to be due to the use of impure DNA as target antigen. Other false positive results were recorded which may have been due to other nuclear components or IgM antibodies. The very high false positivity for the IDS RIA was felt to be due, in large part, to the non-specific coprecipitation of labelled DNA. The in-house method used here clearly shows that specificity requires a combination of highly purified target antigen, the detection of IgG antibodies alone and low non-specific binding.
